Canadian pharmaceutical company Valeant is suing its insurers as it seeks to claw back more than $325mn in costs, as well as unspecified damages, arising from class actions following its attempted acquisition of drug firm Allergan.
Canadian pharmaceutical company Valeant is suing its insurers as it seeks to claw back more than $325mn in costs, as well as unspecified damages, arising from class actions following its attempted acquisition of drug firm Allergan.